VIR BIOTECHNOLOGY, INC.

Ticker: VIR

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vigtige Datoer:

1. Kvartalsregnskab: N/A

2. Kvartalsregnskab: N/A

3. Kvartalsregnskab: N/A

4. Kvartalsregnskab: 26. Feb. - 2025 var for 194 dage siden!

Årsregnskab: N/A

x-day: N/A

Loading...
Loading...
Loading...
Valuta: USD 2025 2024 2023 2022 2021
Revenue * 74.205.000 86.180.000 1.615.797.000 1.095.415.000
Income Before Tax * -523.105.000 -628.194.000 754.280.000 549.802.000
Income After Tax * * * * *
Shareholder Equity * 1.150.385.000 1.590.236.000 2.077.963.000 *
Equity * 1.150.385.000 1.590.236.000 2.077.963.000 1.431.849.000

ROE: %

P/E:

P/B:

Owner Earnings beregning for Vir Biotechnology, Inc. år 2024

Owner earnings beregningen er en af de beregninger, Warren Buffet bruger til at vurdere et firmas indre værdi. Buffet har beskrevet den i Berkshire Hathaway's årsrapport fra 1986.

Tanken er, at man beregner firmaets totale værdi og deler den med antallet af aktier. Dette tal ganger man med ti (år). Så får man den højeste pris, som man skal betale for aktien som langsigtet (ti år) investor.

2025 2024
Overskud før skat (Income Statement) * -523.105.000
Af- og nedskrivninger (Cash Flow: Operating Activities) * *
Ændring i receivables (Cash Flow: Operating Activities) * *
Ændring i payables (Cash Flow: Operating Activities) * *
Vedligehold (Cash Flow: Investing Activities) * *
Owner Earnings / år: 0 -523.105.000
Owner Earnings / aktie: * -523.105